Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients (Q33387348)

26 July 2017

Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients (English)

1 reference

systemic lupus erythematosus

26 July 2017

0 references

author

Aurelio López-Colombo

object named as

A Lopez-Colombo

12

0 references

author name string

M Garcia-Carrasco

1

1 reference

26 July 2017

C Mendoza-Pinto

2

1 reference

26 July 2017

M Sandoval-Cruz

3

1 reference

26 July 2017

E Soto-Vega

4

1 reference

26 July 2017

A Beltran-Castillo

5

1 reference

26 July 2017

M Jimenez-Hernandez

6

1 reference

26 July 2017

D Graillet

7

1 reference

26 July 2017

L Gonzalez

8

1 reference

26 July 2017

J Rojas-Rodriguez

9

1 reference

26 July 2017

A Pineda-Almazana

10

1 reference

26 July 2017

L Zamudio-Huerta

11

1 reference

26 July 2017

4 December 2009

1 reference

26 July 2017

1 reference

26 July 2017

19

1 reference

26 July 2017

2

1 reference

26 July 2017

213-219

1 reference

Systemic lupus erythematosus.

26 July 2017

1 reference

https://api.crossref.org/works/10.1177%2F0961203309351541

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309351541

Use of rituximab in patients with systemic lupus erythematosus: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309351541

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309351541

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309351541

Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309351541

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309351541

An open study of B lymphocyte depletion in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309351541

B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309351541

Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309351541

The 1982 revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309351541

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309351541

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309351541

Should Rituximab be Considered as the First-Choice Treatment for Severe Autoimmune Rheumatic Diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309351541

Systemic lupus erythematosus in 6 male cocaine users at Bellevue hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309351541

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309351541

Outcomes in African Americans and Hispanics with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309351541

Rituximab for Immune Cytopenia in Adults: Idiopathic Thrombocytopenic Purpura, Autoimmune Hemolytic Anemia, and Evans Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309351541

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309351541

Effective B cell depletion with rituximab in the treatment of autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309351541

Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309351541

Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309351541

21 January 2018

Identifiers

DOI

10.1177/0961203309351541

1 reference

26 July 2017

1 reference